Sunitinib

Overview

Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.[1][2] WP

As of August 2021, sunitinib is available as a generic medicine in the US.[3] WP

Uses, dosage and effects

Gastrointestinal stromal tumor

Like renal cell carcinoma, gastrointestinal stromal tumors do not generally respond to standard chemotherapy or radiation. Imatinib was the first chemotherapeutic agent proven effective for metastatic gastrointestinal stromal tumors and represented a significant development in the treatment of this rare but challenging disease. However, approximately 20% of patients do not respond to imatinib (early or primary resistance), and among those who do respond initially, 50% develop secondary imatinib resistance and disease progression within two years. Before sunitinib, patients had no therapeutic option once they became resistant to imatinib.[4] WP

Sunitinib offers patients with imatinib-resistant gastrointestinal stromal tumors a new treatment option to stop further disease progression and, in some cases, even reverse it. This was shown in a large phase III clinical trial in which patients who failed imatinib therapy (due to primary or secondary resistance or intolerance) were treated in a randomized and blinded fashion with either sunitinib or placebo.[4] WP

The study was unblinded early—at the first interim analysis—due to the clearly emerging benefit of sunitinib. Patients receiving a placebo were offered to switch to sunitinib at that time. In the primary endpoint of the study, the median time to tumor progression (TTP) was more than four-fold longer with sunitinib (27 weeks) compared with placebo (six weeks, P<.0001), based on an independent radiological assessment. The benefit of sunitinib remained statistically significant when stratified by many prespecified baseline variables.[4] WP

Among the secondary endpoints, the difference in progression-free survival (PFS) was similar to that in TTP (24 weeks vs. six weeks, P<.0001). Seven percent of sunitinib patients had significant tumor shrinkage (objective response) compared to 0% of patients receiving placebo (P=.006). Another 58% of sunitinib patients had disease stabilization vs. 48% of patients receiving placebo. The median time to response with sunitinib was 10.4 weeks. Sunitinib reduced the relative risk of disease progression or death by 67% and the risk of death alone by 51%. The difference in survival benefit may be diluted because placebo patients crossed over to sunitinib upon disease progression, and most of these patients subsequently responded to sunitinib.[4] WP

Sunitinib was relatively well tolerated. About 83% of sunitinib patients experienced a treatment-related adverse event of any severity, as did 59% of patients who received placebo. Serious adverse events were reported in 20% of sunitinib patients and 5% of placebo patients. Adverse events were generally moderate and easily managed by dose reduction, dose interruption, or other treatment. Nine percent of sunitinib patients and 8% of placebo patients discontinued therapy due to an adverse event.[4] WP

Fatigue is the adverse event most commonly associated with sunitinib therapy. In this study, 34% of sunitinib patients reported any fatigue, compared with 22% for placebo. The grade 3 (severe) fatigue incidence was similar between the two groups, and no grade 4 fatigue was reported.[4] WP

Meningioma

Sunitinib is being studied for the treatment of meningioma, which is associated with neurofibromatosis.[5] WP

Aggressive fibromatosis

As of 2024, sunitinib is being studied for aggressive fibromatosis (desmoid tumors).[6] WP

Pancreatic neuroendocrine tumors

In November 2010, sunitinib was authorized in the European Union for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression in adults. In May 2011, the USFDA approved sunitinib for treating people with 'progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery, or that has spread to other parts of the body (metastatic).[7][8] WP

Renal cell carcinoma

Sunitinib is approved for the treatment of metastatic renal cell carcinoma. Renal cell carcinoma is generally resistant to chemotherapy or radiation. Before RTKs, metastatic disease could only be treated with the cytokines interferon alpha (IFNα) or interleukin-2. However, these agents demonstrated low rates of efficacy (5%-20%).[9] WP

In a phase III study, median progression-free survival was significantly longer in the sunitinib group (11 months) than in the IFNα group (five months), with a hazard ratio of 0.42. In the secondary endpoints, 28% had significant tumor shrinkage with sunitinib compared to 5% with IFNα. Patients receiving sunitinib had a better quality of life than IFNα. An update in 2008 showed that the primary endpoint of median progression-free survival (PFS) remained superior with sunitinib: 11 months versus 5 months for IFNα, P<.000001. Objective response rate also remained superior: 39-47% for sunitinib versus 8-12% with IFNα, P<.000001.[1][9][10][11] WP

Sunitinib treatment trended towards a slightly longer overall survival, although this was not statistically significant. WP

• Median overall survivability was 26 months with sunitinib vs 22 months for IFNα regardless of stratification (P-value ranges from.051 to.0132, depending on statistical analysis). WP
• The first analysis includes 25 patients initially randomized to IFNα who crossed over to sunitinib therapy, which may have confounded the results; in an exploratory analysis that excluded these patients, the difference becomes more robust: 26 vs 20 months, P=.0081. WP
• Patients in the study were allowed to receive other therapies once they had progressed on their study treatment. For a "pure" analysis of the difference between the two agents, an analysis was done using only patients who did not receive any post-study treatment. This analysis demonstrated the greatest advantage for sunitinib: 28 months vs 14 months for IFNα, P=.0033. The number of patients in this analysis was small, which does not reflect actual clinical practice; therefore, it is not meaningful. WP

Hypertension (HTN) was found to be a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. Patients with mRCC and sunitinib-induced hypertension had better outcomes than those without treatment-induced HTN.[12] WP

Risks and side effects

Side effects

Sunitinib adverse events are considered somewhat manageable and the incidence of serious adverse events low.[4][9] WP

The most common adverse events associated with sunitinib therapy are fatigue, diarrhea, nausea, anorexia, hypertension, a yellow skin discoloration, hand-foot skin reaction, and stomatitis. In the placebo-controlled Phase III GIST study, adverse events which occurred more often with sunitinib than placebo included diarrhea, anorexia, skin discoloration, mucositis/stomatitis, asthenia, altered taste, and constipation.[1][4][13] WP

Serious (grade 3 or 4) adverse events occur in ≤10% of patients and include hypertension, fatigue, asthenia, diarrhea, and chemotherapy-induced acral erythema. Lab abnormalities associated with sunitinib therapy include lipase, amylase, neutrophils, lymphocytes, and platelets. Hypothyroidism and reversible erythrocytosis have also been associated with sunitinib.[1][14] WP

A study done at MD Anderson Cancer Center compared the outcomes of metastatic renal cell cancer patients who received sunitinib on the standard schedule (50 mg/4 weeks on 2 weeks off) with those who received sunitinib with more frequent and short drug holidays (alternative schedule). It was seen that the overall survival, progression free survival and drug adherence were significantly higher in the patients who received Sunitinib on the alternative schedule. Patients also had a better tolerance and lower severity of adverse events which frequently lead to discontinuation of treatment of metastatic renal cell cancer patients.[15] WP

Interactions

Interactions

Epigallocatechin-3-gallate, a major constituent of green tea, may reduce the bioavailability of sunitinib when they are taken together.[16] WP

Pharmacology

Mechanism of action

Sunitinib inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs). WP

These include all receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), which play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous inhibition of these targets therefore reduces tumor vascularization and triggers cancer cell apoptosis and thus results in tumor shrinkage. WP

Sunitinib also inhibits CD117 (c-KIT), the receptor tyrosine kinase that (when improperly activated by mutation) drives the majority of gastrointestinal stromal cell tumors. It has been recommended as a second-line therapy for patients whose tumors develop mutations in c-KIT that make them resistant to imatinib, or who the cannot tolerate the drug.[17–20] WP

In addition, sunitinib binds other receptors. These include:[1] WP

• RET[1] WP
• CD114[1] WP
• CD135[1] WP

The fact that sunitinib targets many different receptors, leads to many of its side effects such as the classic hand-foot syndrome, stomatitis, and other dermatologic toxicities. WP

Research

Other solid tumors

The efficacy of sunitinib is currently being evaluated in a broad range of solid tumors, including breast, lung, thyroid and colorectal cancers. Early studies have shown single-agent efficacy in a number of different areas. Sunitinib blocks the tyrosine kinase activities of KIT, PDGFR, VEGFR2 and other tyrosine kinases involved in the development of tumours. WP

• A Phase II study in previously treated patients with metastatic breast cancer found sunitinib “has significant single agent activity”.[21] WP
• A phase II study of refractory non-small-cell lung cancer found “Sunitinib has provocative single-agent activity in previously treated pts with recurrent and advanced NSCLC, with the level of activity similar to currently approved agents.”[22] WP
• In a phase II study of patients with nonresectable neuroendocrine tumors, 91% of patients responded to sunitinib (9% partial response + 82% stable disease).[23] WP
• Sunitinib was found to protect JIMT-1 breast cancer cells against natural killer cell-mediated cytotoxicity, which was claimed to block the anticancer immune response. If sunitinib were to be paired with anticancer immunotherapies, this finding might need to be taken into account.[24] WP

Leukemia

Sunitinib was used to treat the leukemia of a Washington University in St. Louis leukemia researcher who developed the disease himself. His team used genetic sequencing and noticed that the FLT3 gene was hyperactive in his leukemia cells and used sunitinib as a treatment.[25] WP

Unsuccessful trials

Between April 2009 and May 2011, Pfizer has reported unsuccessful late-stage trials in breast cancer, metastatic colorectal cancer, advanced non-small-cell lung cancer, and castration-resistant prostate cancer.[26] WP

History

History

The drug was discovered at SUGEN, a biotechnology company which pioneered protein kinase inhibitors. It was the third in a series of compounds including SU5416 and SU6668. The concept was of an ATP mimic that would compete with ATP for binding to the catalytic site of receptor tyrosine kinases. This concept led to the invention of many small-molecule tyrosine kinase inhibitors, including Gleevec, Sutent, Tarceva and many others. WP⚠ Wikipedia itself has flagged this text: citation needed.

Legal status

Economics

Sunitinib is marketed by Pfizer as Sutent, and was subject to patents and market exclusivity as a new chemical entity until 15 February 2021. Sutent has been cited in financial news as a potential revenue source to replace royalties lost from Lipitor following the expiration of the latter drug's patent expiration in November 2011. Sutent is one of the most expensive drugs widely marketed. Doctors and editorials have criticized the high cost for a drug that does not cure cancer, but only prolongs life.[27–30] WP⚠ Wikipedia itself has flagged this text: citation needed.

US

In the U.S., many insurance companies have refused to pay for all or part of the costs of Sutent. Because it is an oral therapy, the copay associated with this therapy can be very substantial. If a patient's secondary insurance does not cover this, the cost burden to the patient can be extreme. Particularly challenging is the Medicare Part D coverage gap. Patients have to spend thousands of dollars out-of-pocket during the gap in coverage. If this is done at the end of a calendar year, it has to be paid again at the beginning of the next calendar year, which may be burdensome financially. WP

UK

In the UK, NICE refused (late 2008) to recommend sunitinib for late-stage renal cancer (kidney cancer) due to the high cost per QALY, estimated by NICE at £72,000/QALY and by Pfizer at £29,000/QALY. This was overturned in February 2009 after pricing changes and public responses. Therefore, sunitinib is recommended as a first-line treatment option for people with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an ECOG performance status of 0 or 1 (i.e. completely ambulatory).[31–34] WP

Au

Sunitinib is available in Australia and is subsidized by the Pharmaceutical Benefits Scheme for Stage IV Renal Cell Carcinoma (RCC). The cost to the patient who meets the clinical criteria of Stage IV RCC is AUD $35.40 for 28 capsules, regardless of dose. Manufacturer pricing for sunitinib ranges from AUD $1,834.30 to AUD $6897.54, depending on dose (12.5 mg to 50 mg).[35] WP

Chemistry

Formula

C22H27FN4O2 PC

CAS number

557795-19-4 PC

Molar mass (g/mol)

398.5 PC

IUPAC name (computed by PubChem)

N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide PC

SMILES

CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C PC

InChIKey

WINHZLLDWRZWRT-ATVHPVEESA-N PC

PubChem CID

5329102

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Sutent- sunitinib malate capsule
2. Journal / agency FDA approves new treatment for gastrointestinal and kidney cancer. 2006
3. Journal / agency Sunitinib malate: FDA-Approved Drugs
4. Journal / agency Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. October 2006. doi:10.1016/S0140-6736(06)69446-4 · PMID 17046465
5. Other Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma. 21 December 2015
6. Journal / agency Mangla A, Agarwal N, Schwartz G. Desmoid Tumors: Current Perspective and Treatment. Current Treatment Options in Oncology. February 2024. doi:10.1007/s11864-024-01177-5 · PMID 38270798 · PMC10873447
7. Other Pfizer Scores New Approval for Sutent in Europe. 2 December 2010
8. Journal / agency FDA approves Sutent for rare type of pancreatic cancer. 20 May 2011
9. Journal / agency Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of Medicine. January 2007. doi:10.1056/NEJMoa065044 · PMID 17215529
10. Journal / agency Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Négrier S, Huang X, Kim ST, Chen I, Motzer NJ. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 2008. doi:10.1200/jco.2008.26.15_suppl.5024
11. Journal / agency Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. August 2009. doi:10.1200/JCO.2008.20.1293 · PMID 19487381 · PMC3646307
12. Journal / agency Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. | CureHunter
13. Journal / agency Dasanu CA, Alexandrescu DT, Dutcher J. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. Southern Medical Journal. March 2007. doi:10.1097/smj.0b013e31802f01a9 · PMID 17396743
14. Journal / agency Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. Journal of Clinical Oncology. August 2008. doi:10.1200/jco.2008.18.3525 · PMID 18711201
15. Journal / agency Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. The Journal of Urology. March 2014. doi:10.1016/j.juro.2013.08.090 · PMID 24018239 · PMC4015627
16. Journal / agency Ge J, Tan BX, Chen Y, Yang L, Peng XC, Li HZ, Lin HJ, Zhao Y, Wei M, Cheng K, Li LH, Dong H, Gao F, He JP, Wu Y, Qiu M, Zhao YL, Su JM, Hou JM, Liu JY. Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. Journal of Molecular Medicine. June 2011. doi:10.1007/s00109-011-0737-3 · PMID 21331509
17. Journal / agency Hartmann JT, Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Archives of Dermatology. November 2008. doi:10.1001/archderm.144.11.1525 · PMID 19015436
18. Journal / agency Quek R, George S. Gastrointestinal stromal tumor: a clinical overview. Hematology/Oncology Clinics of North America. February 2009. doi:10.1016/j.hoc.2008.11.006 · PMID 19248971
19. Journal / agency Blay JY, Reichardt P. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Expert Review of Anticancer Therapy. June 2009. doi:10.1586/era.09.34 · PMID 19496720
20. Journal / agency Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opinion on Investigational Drugs. June 2009. doi:10.1517/13543780902980171 · PMID 19453268
21. Journal / agency Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Pegram MD, Eisenberg PD, Collier M, Adams BJ, Baum CM. Phase II study of SU11248, a multi-targeted tyrosine kinase inhibitor in patients with previously treated metastatic breast cancer. Presented at ASCO 2005
22. Journal / agency Socinski MA, Novello S, Sanchez JM, Brahmer JA, Govindan R, Belani CP, Atkins JN, Gillenwater HH, Palleres C, Chao RC. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006
23. Journal / agency Kulke M, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Baum CM, Fuchs CS. A Phase 2 Study to Evaluate the Efficacy of SU11248 in Patients with Unresectable Neuroendocrine Tumors. Presented at ASCO 2005
24. Journal / agency Guti E, Regdon Z, Sturniolo I, Kiss A, Kovács K, Demény M, Szöőr Á, Vereb G, Szöllősi J, Hegedűs C, Polgár Z, Virág L. The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC. Cancer Immunology, Immunotherapy. September 2022. doi:10.1007/s00262-022-03146-z · PMID 35066605 · PMC9374626
25. Other Kolata G. In Gene Sequencing Treatment for Leukemia, Glimpses of the Future. 7 July 2012
26. Other FDA Expands Sutent Label to Include Pancreatic Neuroendocrine Tumors. 23 May 2011
27. Journal / agency Patent and Exclusivity Search Results from query on Appl No 021938 Product 003 in the OB_Rx list
28. Other Details for Generic 'Sunitinib Malate'
29. Other Jamie Dlugosch. Will biologics and Sutent save Pfizer?. 13 March 2009
30. Other Zacks Investment Research. Pfizer's a Sell: Shrinking Top Line, No Blockbusters In the Pipeline. 22 March 2007
31. Other BMJ 31 January 2009 "NICE and the challenge of cancer drugs" p.271 fcn
32. Other 'We'll sell our house for this drug'. 7 August 2008
33. Other Devlin, Kate. Kidney cancer patients should get Sutent on the NHS, says NICE. 24 May 2010
34. Other Renal cancer
35. Other Pharmaceutical Benefits Scheme (PBS)

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.